Having one of the industry's largest portfolios of anti-infective drugs allows Merck & Co. Inc. to weather the various storms within this sector of the biopharmaceutical industry, where there is a major need for new medicines to combat antimicrobial resistance (AMR), but where stewardship is required to make sure overuse doesn't worsen the AMR crisis.
Merck has a long history of developing antibiotics and antifungals, and has stuck with the challenging therapeutic area because of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
